EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Iron Chelation Therapy

Maria Domenica Cappellini, Natalia Scaramellini, Simona Leoni, Irene Motta

Advances in Experimental Medicine and Biology · 2025

DOI: 10.1007/978-3-031-92033-2_23 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Experimental Medicine and Biology, 2025. Verfasst von Maria Domenica Cappellini und 3 weiteren Autor:innen. Beteiligte Einrichtung: SC Medicina ad Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. maria.cappellini@unimi.it. Hauptthemen laut MEDLINE: Iron Chelating Agents, Iron Overload, Chelation Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Iron overload is a serious complication associated with transfusion-dependent anemias and anemias characterized by ineffective erythropoiesis. Iron accumulation is toxic to many tissues, causing heart failure, cirrhosis, liver cancer, growth retardation, and multiple endocrine abnormalities.Chelation therapy aims to balance the rate of iron accumulation from blood transfusions by increasing iron excretion in urine and/or feces with chelators. Three iron chelators are currently available to treat patients: one administered parenterally called deferoxamine (or desferrioxamine) and two oral chelators, deferiprone and deferasirox. Careful dose adjustment is necessary to avoid excess chelation as iron levels fall.A key factor for successful iron chelation is to achieve regular adherence to treatment regimens throughout life: while the convenience and tolerability of individual chelators are important in achieving this goal, other factors such as psychological well-being and family and institutional support also impact adherence and outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Iron Chelating AgentsIron OverloadChelation TherapyHumansIronPyridonesDeferoxamineDeferiproneDeferasirox

Stichwörter der Autor:innen

DeferasiroxDeferiproneDeferoxamineIron overloadTransfusion-dependent anemias

Substanzen

Iron Chelating AgentsIronPyridonesDeferoxamineDeferiproneDeferasirox

Autor:innen und Institutionen

  • SC Medicina ad Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. maria.cappellini@unimi.it.
  • SC Medicina ad Indirizzo Metabolico, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Dipartimento di Scienze Cliniche e di Comunità, Dipartimento di Eccellenza 2023-2027, University of Milan, Milan, Italy.

Zitieren

APA

Cappellini, M. D., Scaramellini, N., Leoni, S., & Motta, I. (2025). Iron Chelation Therapy. Advances in Experimental Medicine and Biology. https://doi.org/10.1007/978-3-031-92033-2_23

Vancouver

Cappellini MD, Scaramellini N, Leoni S, Motta I. Iron Chelation Therapy. Advances in Experimental Medicine and Biology. 2025. doi:10.1007/978-3-031-92033-2_23

BibTeX
@article{Cappellini2025,
  author = {Cappellini, Maria Domenica and Scaramellini, Natalia and Leoni, Simona and Motta, Irene},
  title = {Iron Chelation Therapy},
  journal = {Advances in Experimental Medicine and Biology},
  year = {2025},
  doi = {10.1007/978-3-031-92033-2_23}
}
Kostenlos starten →